Tarsus Pharmaceuticals Inc (TARS NASDAQ) stock market data APIs
$68.5451
0.56(0.8%)
as of November 6, 2025
Try our APIs with
free plan!
Tarsus Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Prev. Close
68.5451
Open
69.1056
High
68.8437
Low
66.8916
52 wk Range
38.51-76.81
Market Cap
2 879 M
Shares Outstanding
42 214 K
Revenue
296 M
EPS
-0.3
Beta
0.761
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tarsus Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tarsus Pharmaceuticals Inc data using free add-ons & libraries
Get Tarsus Pharmaceuticals Inc Fundamental Data
Tarsus Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 296 M
- EBITDA: -96 418 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.3645
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tarsus Pharmaceuticals Inc News
New
Tarsus to Participate in Upcoming Investor Conference
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2nd Annual He...
Tarsus to Participate in Upcoming Investor Conference
Tarsus Pharmaceuticals, Inc IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at t...
Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ...
This article first appeared on GuruFocus. Release Date: November 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tarsu...
Tarsus outlines $140M–$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress
Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q3 2025 MANAGEMENT VIEW * CEO Bobak Azamian highlighted the exceptional performance of XDEMVY, stating, "We delivered more than 103,000 bottle...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
